These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20227877)

  • 1. 2,5-Disubstituted pyridines as potent GPR119 agonists.
    Wu Y; Kuntz JD; Carpenter AJ; Fang J; Sauls HR; Gomez DJ; Ammala C; Xu Y; Hart S; Tadepalli S
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2577-81. PubMed ID: 20227877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Apr; 20(7):2369-75. PubMed ID: 22365911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
    Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of the structure of 4, 6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: synthesis and their 5-HT2A receptor activity.
    Paluchowska MH; Bojarski AJ; Bugno R; Charakchieva-Minol S; Wesołowska A
    Arch Pharm (Weinheim); 2003 Apr; 336(2):104-10. PubMed ID: 12761763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
    Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
    Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent and selective GPR119 agonists for type II diabetes.
    Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
    Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
    Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
    J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
    Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
    Thomas SA; Li T; Woods KW; Song X; Packard G; Fischer JP; Diebold RB; Liu X; Shi Y; Klinghofer V; Johnson EF; Bouska JJ; Olson A; Guan R; Magnone SR; Marsh K; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3740-4. PubMed ID: 16678413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
    Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
    J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel and potent small-molecule urotensin II receptor agonists.
    Lehmann F; Currier EA; Clemons B; Hansen LK; Olsson R; Hacksell U; Luthman K
    Bioorg Med Chem; 2009 Jul; 17(13):4657-65. PubMed ID: 19481466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of phenyl acetamides as potent and selective GPR119 agonists.
    Zhu C; Wang L; Zhu Y; Guo ZZ; Liu P; Hu Z; Szewczyk JW; Kang L; Chicchi G; Ehrhardt A; Woods A; Seo T; Woods M; van Heek M; Dingley KH; Pang J; Salituro GM; Powell J; Terebetski JL; Hornak V; Campeau LC; Orr RK; Ujjainwalla F; Miller M; Stamford A; Wood HB; Kowalski T; Nargund RP; Edmondson SD
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1124-1128. PubMed ID: 28185720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists.
    Budzik BW; Evans KA; Wisnoski DD; Jin J; Rivero RA; Szewczyk GR; Jayawickreme C; Moncol DL; Yu H
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1363-7. PubMed ID: 20097073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of GPR119 receptor activity with endocannabinoid-like lipids.
    Syed SK; Bui HH; Beavers LS; Farb TB; Ficorilli J; Chesterfield AK; Kuo MS; Bokvist K; Barrett DG; Efanov AM
    Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1469-78. PubMed ID: 23074242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triamino pyrimidines and pyridines as histamine H(4) receptor modulators.
    Meduna SP; Savall BM; Cai H; Edwards JP; Thurmond RL; McGovern PM
    Bioorg Med Chem Lett; 2011 May; 21(10):3113-6. PubMed ID: 21458260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.